chr11-17397055-C-T
Position:
Variant summary
Our verdict is Pathogenic. Variant got 10 ACMG points: 10P and 0B. PM2PP5_Very_Strong
The NM_000352.6(ABCC8):āc.3989-9G>A variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000185 in 1,614,150 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Pathogenic (ā ā ).
Frequency
Genomes: š 0.00018 ( 0 hom., cov: 33)
Exomes š: 0.00019 ( 0 hom. )
Consequence
ABCC8
NM_000352.6 intron
NM_000352.6 intron
Scores
2
Splicing: ADA: 0.001703
1
Clinical Significance
Conservation
PhyloP100: 0.305
Genes affected
ABCC8 (HGNC:59): (ATP binding cassette subfamily C member 8) The protein encoded by this gene is a member of the superfamily of ATP-binding cassette (ABC) transporters. ABC proteins transport various molecules across extra- and intra-cellular membranes. ABC genes are divided into seven distinct subfamilies (ABC1, MDR/TAP, MRP, ALD, OABP, GCN20, White). This protein is a member of the MRP subfamily which is involved in multi-drug resistance. This protein functions as a modulator of ATP-sensitive potassium channels and insulin release. Mutations in the ABCC8 gene and deficiencies in the encoded protein have been observed in patients with hyperinsulinemic hypoglycemia of infancy, an autosomal recessive disorder of unregulated and high insulin secretion. Mutations have also been associated with non-insulin-dependent diabetes mellitus type II, an autosomal dominant disease of defective insulin secretion. Alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Jul 2020]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 10 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 11-17397055-C-T is Pathogenic according to our data. Variant chr11-17397055-C-T is described in ClinVar as [Pathogenic]. Clinvar id is 9088.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ABCC8 | NM_000352.6 | c.3989-9G>A | intron_variant | ENST00000389817.8 | NP_000343.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ABCC8 | ENST00000389817.8 | c.3989-9G>A | intron_variant | 1 | NM_000352.6 | ENSP00000374467.4 |
Frequencies
GnomAD3 genomes AF: 0.000177 AC: 27AN: 152194Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
27
AN:
152194
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000326 AC: 82AN: 251406Hom.: 0 AF XY: 0.000316 AC XY: 43AN XY: 135884
GnomAD3 exomes
AF:
AC:
82
AN:
251406
Hom.:
AF XY:
AC XY:
43
AN XY:
135884
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000185 AC: 271AN: 1461838Hom.: 0 Cov.: 34 AF XY: 0.000198 AC XY: 144AN XY: 727220
GnomAD4 exome
AF:
AC:
271
AN:
1461838
Hom.:
Cov.:
34
AF XY:
AC XY:
144
AN XY:
727220
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000177 AC: 27AN: 152312Hom.: 0 Cov.: 33 AF XY: 0.000134 AC XY: 10AN XY: 74474
GnomAD4 genome
AF:
AC:
27
AN:
152312
Hom.:
Cov.:
33
AF XY:
AC XY:
10
AN XY:
74474
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:18
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Pathogenic:7
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 27, 2024 | This sequence change falls in intron 32 of the ABCC8 gene. It does not directly change the encoded amino acid sequence of the ABCC8 protein. This variant is present in population databases (rs151344623, gnomAD 0.6%). This variant has been observed in individual(s) with autosomal recessive familial hyperinsulinism (PMID: 7716548, 27754802). It is commonly reported in individuals of Ashkenazi Jewish ancestry (PMID: 8923011, 21716120). This variant is also known as 3992āĆƬ9gāĆĆa. ClinVar contains an entry for this variant (Variation ID: 9088). Studies have shown that this variant alters mRNA splicing and is expected to lead to the loss of protein expression (PMID: 7716548). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Athena Diagnostics | Apr 11, 2017 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Jun 13, 2014 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Genomic Diagnostic Laboratory, Division of Genomic Diagnostics, Children's Hospital of Philadelphia | Oct 07, 2015 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Dec 20, 2023 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jan 25, 2022 | Published functional studies suggest that c.3989-9G>A activates a preexisting cryptic 3splice site within exon 33, resulting in out-of-frame product (Saint-Martin et al., 2021); In silico analysis supports a deleterious effect on splicing; This variant is associated with the following publications: (PMID: 25972930, 7716548, 8923011, 20672374, 27754802, 21716120, 25306193, 31980526, 31589614, 33726816, 33410562) - |
Pathogenic, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Jul 23, 2013 | - - |
Hyperinsulinemic hypoglycemia, familial, 1 Pathogenic:4
Pathogenic, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Dec 26, 2019 | NM_000352.3(ABCC8):c.3989-9G>A is classified as pathogenic in the context of ABCC8-related familial hyperinsulinism. Sources cited for classification include the following: PMID 10447255, 7716548, 23345197, 11999683, 11272143, 24401662, 15579781, 21851374, 16860127 and 8923011. Classification of NM_000352.3(ABCC8):c.3989-9G>A is based on the following criteria: This is a well-established pathogenic variant in the literature that has been observed more frequently in patients with clinical diagnoses than in healthy populations. Please note: this variant was assessed in the context of healthy population screening. - |
Pathogenic, criteria provided, single submitter | curation | Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard | Aug 16, 2023 | The c.3989-9G>A variant in ABCC8 has been reported in >10 individuals with hyperinsulinemic hypoglycemia (PMID: 25306193, 25972930, 16429405, 16860127, 27175728, 17378627, 11272143, 27754802), and has been identified In 0.6% (62/10366) or Ashkenazi Jewish chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs151344623). Although this variant has been seen in the general population in a heterozygous state, its frequency is not high enough to rule out a pathogenic role. This variant has also been reported in ClinVar (Variation ID: 9088) and has been interpreted as pathogenic by multiple sources. Of the many affected individuals, at least 3 were compound heterozygotes that carried a reported pathogenic variant in trans, and 4 of those were homozygotes, which increases the likelihood that the c.3989-9G>A variant is pathogenic (Variation ID: 188864, 9096; PMID: 16429405, 16860127, 17378627). RNAseq analysis performed on affected tissue shows a deletion of the first 20 nucleotides of exon 33 (PMID: 33410562). This variant is located in the 3ā splice region. Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive hyperinsulinemic hypoglycemia. ACMG/AMP Criteria applied: PM3_very_strong, PS3, PP3 (Richards 2015). - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Jan 01, 1999 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | 3billion | May 22, 2022 | The variant is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.029%). In silico tools predict the variant to alter splicing and produce an abnormal transcript (SpliceAI: 0.70). The variant has been reported to be in trans with a pathogenic variant as either compound heterozygous or homozygous in at least one similarly affected unrelated individual (PMID: 25306193) and co-segregate with the disease in at least one similarly affected relative/individual in the same family or similarly affected unrelated family (PMID: 27754802, 7716548). The variant has been reported at least twice as pathogenic with clinical assertions and evidence for the classification (ClinVar ID: VCV000009088). Therefore, this variant is classified as pathogenic according to the recommendation of ACMG/AMP guideline. - |
Familial hyperinsulinism Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jun 05, 2017 | Variant summary: The ABCC8 variant, c.3989-9G>A (alternatively also known as 3992-9G>A) involves the alteration of a non-conserved intronic nucleotide in intron 32. Mutation taster predicts a disease-causing outcome for this variant. While Human Splicing Finder predicts this variant to form a cryptic splice acceptor site, other four splice prediction tools predict no significant impact on normal splicing. Functional study shows that this variant leads to aberrant splicing, resulting in a 7-bp addition, a 20-bp deletion, or 30-bp deletion of exon 32 that encodes NBF-2 (nucleotide binding fold 2) of the protein (Thomas_1995). This variant was found in 373/164074 control chromosomes including ExAC at a frequency of 0.0022734, which does not exceed the estimated maximal expected allele frequency of a pathogenic ABCC8 variant (0.0033541). This variant is a known common pathogenic variant causing congenital hyperinsulinism (CH). In Ashkenazi population, c.39899G>A and p.F1387del are the two most common CH-associated ABCC8 mutations (Nestorowicz_1998, Glaser_2011). Carrier rate of this mutation in Ashkenazi general population is 1:60 (Glaser_2011). In GeneReviews, proportion of familial CH attributed to these two mutations is estimated to be nearly 45%. Multiple clinical diagnostic laboratories/reputable databases have classified this variant as pathogenic. Taken together, this variant is classified as pathogenic. - |
Pathogenic, no assertion criteria provided | curation | Reproductive Health Research and Development, BGI Genomics | Jan 06, 2020 | NG_008867.1(NM_001287174.1):c.3992-9G>A in the ABCC8 gene has an allele frequency of 0.006 in Ashkenazi Jewish subpopulation in the gnomAD database. This variant has been observed to segregate with familial hyperinsulinism and affect RNA splicing (PMID: 7716548). In addition, Gutgold et al. reported a male with recurrent hypoglycemia episodes and revealed a homozygosity for c.3992-9G>A (PMID: 27754802). Experimental studies have shown that this intronic change alters ABCC8 splicing (PMID: 7716548). Taken together, we interprete this variant as Pathogenic/Likely pathogenic. ACMG/AMP Criteria applied: PS4; PS3; PM3; PP4. - |
Hyperinsulinemic hypoglycemia, familial, 1;C5394303:Diabetes mellitus, permanent neonatal 3 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | New York Genome Center | Jan 07, 2022 | - - |
Type 2 diabetes mellitus Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 30, 2024 | - - |
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | May 04, 2022 | The c.3989-9G>A intronic alteration results from a G to A substitution 9 nucleotides before coding exon 33 of the ABCC8 gene. Based on the available evidence, the ABCC8 c.3989-9G>A alteration is classified as pathogenic for familial hyperinsulinemic hypoglycemia, but is unlikely to be causative of autosomal dominant ABCC8-related diabetes mellitus. This alteration has been reported in the homozygous and compound heterozygous states and in the heterozygous state on the paternal allele in multiple individuals with congenital hyperinsulinemic hypoglycemia (Del Roio Liberatore, 2015; Glaser, 2011; Gutgold, 2017; Nestorowicz, 1996; Thomas, 1995). This is also a common founder mutation in the Ashkenazi Jewish population (Glaser, 2011; Nestorowicz, 1996). This nucleotide position is not well conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice acceptor site. Based on the available evidence, this alteration is classified as pathogenic. - |
Hereditary hyperinsulinism Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
ABCC8-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | May 03, 2024 | The ABCC8 c.3989-9G>A variant is predicted to interfere with splicing. This variant has been previously reported to be pathogenic for persistent hyperinsulinemic hypoglycemia due to defective splicing (Thomas et al. 1995. PubMed ID: 7716548; Nestorowicz et al. 1996. PubMed ID: 8923011). In Family 4 of the Thomas et al. study, this variant occurred in the homozygous state in two affected siblings and was heterozygous in both unaffected parents. In the Nestorowicz et al. study, out of the 23 probands who had this variant, 11 were homozygotes and 12 were heterozygotes. This variant is reported in 0.60% of alleles in individuals of Ashkenazi Jewish descent in gnomAD. In summary, this variant is interpreted as pathogenic. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
Splicing
Name
Calibrated prediction
Score
Prediction
dbscSNV1_ADA
Benign
SpliceAI score (max)
Details are displayed if max score is > 0.2
DS_AG_spliceai
Position offset: -2
DS_AL_spliceai
Position offset: -9
Find out detailed SpliceAI scores and Pangolin per-transcript scores at